(0.32%) 5 116.05 points
(0.31%) 38 359 points
(0.35%) 15 984 points
(-0.86%) $83.13
(5.77%) $2.03
(0.37%) $2 355.80
(0.50%) $27.67
(4.02%) $959.15
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 11.83%
@ $29.86
発行日: 12 3月 2024 @ 00:11
リターン: -25.52%
前回のシグナル: 3月 11 - 22:31
前回のシグナル:
リターン: -1.35 %
Live Chart Being Loaded With Signals
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency...
Stats | |
---|---|
本日の出来高 | 612 575 |
平均出来高 | 1.54M |
時価総額 | 2.14B |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $-1.350 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.10 |
ATR14 | $0.0310 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Dube Michael P | Sell | 0 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 37 966 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 54 794 | Stock Option (right to buy) |
2024-03-01 | Basta James | Buy | 32 394 | Common Stock |
2024-03-04 | Basta James | Sell | 2 297 | Common Stock |
INSIDER POWER |
---|
85.54 |
Last 100 transactions |
Buy: 1 561 723 | Sell: 123 854 |
ボリューム 相関
Intellia Therapeutics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Intellia Therapeutics Inc 相関 - 通貨/商品
Intellia Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $36.28M |
総利益: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2023 |
収益: | $36.28M |
総利益: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2022 |
収益: | $52.12M |
総利益: | $44.55M (85.47 %) |
EPS: | $-6.37 |
FY | 2021 |
収益: | $33.05M |
総利益: | $33.05M (100.00 %) |
EPS: | $-3.78 |
Financial Reports:
No articles found.
Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。